| Cat. No. |
Product Name |
Information |
| PC-49516 |
LCRF-0004
Ron kinase inhibitor
|
LCRF-0004 is a potent and selective RON receptor tyrosine kinase inhibitor with IC50 of 50 nM (ELISA), weakly inhibits c-Met with IC50 of 150 nM and does not inhibit VEGFR2. |
| PC-49513 |
ZanzalintinibXL092
VEGFR/MET/TAM inhibitor
|
XL092 (Zanzalintinib, XL-092) is a novel small molecule multi-receptor tyrosine kinase (RTK) inhibitor, targets MET (IC50=3.0 nM), VEGFR2 (IC50=15.0 nM), and the TAM kinases TYRO3, AXL (IC50=5.8 nM), and MER (IC50=0.6 nM). |
| PC-49451 |
D6808
c-MET inhibitor
|
D6808 is a highly selective and potent macrocyclic c-Met inhibitor with IC50 of 2.9 nM. |
| PC-49280 |
c-MET inhibitor 7
c-MET inhibitor
|
c-MET inhibitor 7 is a potent, highly selective c-MET inhibitor with IC50 of 0.90 and 0.09 μM for wild-type and D1228V c-MET, respectively. |
| PC-49132 |
Dalmelitinib
c-Met inhibitor
|
Dalmelitinib is a potent, selective c-Met tyrosine kinase inhibitor with IC50 of 0.7 nM, inhibits cell growth of gastric cells SNU5 with IC50 of 2.0 nM, binds to the ATP-binding region of c-MET kinase. |
| PC-38624 |
Altiratinib
MET/TIE-2/VEGFR inhibitor
|
Altiratinib (DCC-2701) is a potent c-MET/TIE-2/VEGFR inhibitor with IC50 of 2.7 nM (MET WT), 8.0 nM (TIE2 kinase) and 9.2 nM (VEGFR2), also potently inhibits oncogenic MET mutations in the switch region (residues 1228, 1230, and 1250) with IC50 range of 0.37-6 nM. |
| PC-38395 |
Gemnelatinib
c-Met inhibitor
|
Gemnelatinib (GST-HG161) is a potent and highly selective, orally bioavailable c-Met inhibitor, displays significant antitumor activity in preclinical models, has the potential to be effective in HCC with active c-Met signaling. |
| PC-38394 |
Fosgonimeton
HGF/MET modulator
|
Fosgonimeton (ATH-1017, ATH-1001 prodrug) is a highly specific, small-molecule positive modulator of the HGF/MET neurotrophic system, is a prodrug that rapidly converts into the active metabolite ATH-1001 in plasma. |
| PC-36035 |
AMG-458
c-Met inhibitor
|
AMG-458 (AMG458) is a potent, selective, orally bioavailable c-Met inhibitor with Ki of 1.2 nM (human c-Met). |
| PC-35732 |
PLB-1001
MET inhibitor
|
PLB-1001 (Bozitinib, PLB1001, CBI-3103, CBT-101) is a potent, highly selective, ATP-competitive, BBB-permeable MET kinase inhibitor, potently inhibits MET activity by 95.1% at 2 uM. |
| PC-63568 |
BMS-817378
Met/VEGFR-2 inhibitor
|
BMS-817378 is a prodrug of the dual Met/VEGFR-2 inhibitor BMS-794833.. |
| PC-43511 |
Capmatinib
c-MET inhibitor
|
Capmatinib (INCB-28060, INC-280) is a highly potent, selective, ATP competitive inhibitor of c-MET kinase with IC50 of 0.13 nM. |
